Guardant study suggests sequencing archival tissue misses important genomics alterations
April 1, 2016 – REDWOOD CITY. Guardant Health®, the leader in comprehensive liquid biopsies, announced it will present data on more than 10,000 clinical Guardant360® samples at the American Association for Cancer Research (AACR) 2016 annual meeting.
This first-of-its-kind analysis shows high concordance between genomic alterations detected by Guardant360 and those found in tissue-based population genomics studies derived from public datasets such as The Cancer Genome Atlas and the International Cancer Genome Consortium.
Additionally, Guardant360 detected resistance alterations not seen in treatment-naïve tissue cohorts, including MET amplifications and EGFR T790M. This finding suggests that sequencing archival tissue may miss important evolving alterations and hinder the selection of effective therapies for some late-stage cancer patients. The analysis also found that treatment decisions based on the detection of alterations at very low levels, even below 0.1% mutant-allele frequency, can lead to dramatic clinical response in patients.
The presentation is one of five abstracts highlighting the performance and clinical utility of Guardant Health’s digital sequencing technology that have been accepted for oral and poster presentations at this year’s AACR. The abstracts were submitted by researchers from Tel Aviv University, Thomas Jefferson University, Northwestern University, University of California, San Francisco, the Sungkyunkwan University School of Medicine, and Guardant Health.
Guardant360, the first comprehensive liquid biopsy, has been used by more than 2,000 oncologists to help match patients with advanced cancer to targeted therapies. Guardant Health’s digital sequencing platform allows for comprehensive analysis of all major classes of somatic tumor alterations from a simple blood draw, with near-perfect specificity and high sensitivity.
The schedule of presentations:
Date and Time: Tuesday, April 19 4:20-4:35 pmTitle: Comparison of over 10,000 clinical NGS circulating tumor DNA profiles to tissue-derived genomic compendiaAbstract: 4343Location: Room 243, Morial Convention CenterPoster Board Number: 22Presenter: Oliver Zill, Guardant Health
Date and Time: Sunday, April 17 from 1-5 pmTitle: Salvage MET amplification detection and therapy through cell-free DNA NGS in a progressing lung cancer patientAbstract: 491Location: Section 23Poster Board Number: 8Presenter: Nir Peled, Tel Aviv UniversityCollaborators: Oncotest Teva, Teva Pharmaceuticals
Date and Time: Sunday, April 17 from 1-5 p.m. Title: Managing metastatic breast cancer via serial monitoring with circulating cell-free tumor DNA next generation sequencing testingAbstract: 172Location: Section 6Poster Board Number: 26Presenter: Laura Austin, Thomas Jefferson UniversityCollaborators: Northwestern University
Date and Time: Sunday, April 17 from 1-5 p.m.Title: Post-surgical resection monitoring in early stage colorectal carcinoma patients using a circulating cell-free DNA assay with ultra-high accuracy and specificityAbstract: 506Location: Section 23Poster Board Number: 23Presenter: Stefanie A. MortimerCollaborators: University of California San Francisco, Sungkyunkwan University School of Medicine
Date and Time: Monday, April 18 from 1-5 p.m.Title: A case series of ERBB2 indel driver mutations in non-small cell lung cancer identified by cell-free circulating tumor DNA NGSAbstract: 2240Location: Section 22Poster Board Number: 2Presenters: Laura Austin, Thomas Jefferson UniversityCollaborators: Northwestern University
Guardant Health is also an exhibitor at the 2016 AACR Annual Meeting. Company representatives will be available to provide additional information on Guardant Health and its product, Guardant360, at the company’s booth, #312. To learn more, visit www.guardanthealth.com.
SOURCE Guardant Health